VIVANI MEDICAL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.91 USD | +4.37% |
|
+11.05% | +87.25% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 108M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.94
x | P/E ratio 2025 * |
-3.52
x | Employees | 44 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.37% | ||
| 1 week | +11.05% | ||
| Current month | +17.90% | ||
| 1 month | -0.52% | ||
| 3 months | +77.67% | ||
| 6 months | +101.05% | ||
| Current year | +87.25% |
1 week
1.74
2.00
1 month
1.612.00
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | - | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 1.97 | +3.14% | 179,853 |
| 24-05-15 | 1.91 | +4.37% | 212,198 |
| 24-05-14 | 1.83 | -1.08% | 301,299 |
| 24-05-13 | 1.85 | +2.21% | 82,757 |
| 24-05-10 | 1.81 | +5.23% | 96,955 |
End-of-day quote Nasdaq, May 14, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
04:30pm
- TIDES Conference
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.97
USD
Average target price
8
USD
Spread / Average Target
+306.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +87.25% | 108M | |
| +11.57% | 127B | |
| -5.05% | 11.32B | |
| +3.22% | 9.04B | |
| +38.90% | 5.56B | |
| -21.83% | 4.72B | |
| +8.74% | 3.45B | |
| -6.82% | 2.86B | |
| -13.32% | 2.04B | |
| -6.99% | 2.07B |
- Stock Market
- Equities
- VANI Stock
